Division of Sleep Medicine, Brigham and Women's Hospital - Harvard Medical School, Boston, MA 02115, USA.
Sleep. 2013 Feb 1;36(2):281-5. doi: 10.5665/sleep.2390.
The magnitude of the post-apnea/hypopnea ventilatory overshoot following arousal may perpetuate subsequent respiratory events in obstructive sleep apnea (OSA) patients, potentially contributing to the disorder's severity. As acetazolamide can reduce apnea severity in some patients, we examined the effect of acetazolamide on the ventilatory response to spontaneous arousals in CPAP-treated OSA patients.
We assessed the ventilatory response to arousal in OSA patients on therapeutic CPAP before and after administration of acetazolamide for 7 days.
Sleep research laboratory.
12 (7M/5F) CPAP-treated OSA patients.
Sustained-release acetazolamide 500 mg by mouth twice daily for one week.
A blinded investigator identified spontaneous arousals (3-15 s) during NREM sleep. Breath-by-breath measurements of minute ventilation, end-tidal CO(2), tidal volume, expiratory/inspiratory-time, and total breath duration were determined (4-s intervals) 32 s prior and 60 s following each arousal. Acetazolamide significantly increased resting ventilation (7.3 ± 0.2 L/min versus 8.2 ± 0.4 L/min; P < 0.05) and attenuated the percent increase in ventilation following arousal by ~2.5 fold (122.0% ± 4.4% versus 108.7% ± 3.5% pre-arousal level; P < 0.05). There was a positive correlation between the mean increase in ventilatory response to arousal and mean AHI (r(2) = 0.44, P = 0.01). However, absolute peak levels of ventilation following arousal remained unchanged between conditions (8.8 ± 0.4 L/min versus 8.9 ± 0.1 L/min).
Acetazolamide substantially attenuates the increase in ventilation following spontaneous arousal from sleep in OSA patients. This study suggests an additional mechanism by which acetazolamide may contribute to the improvement in ventilatory instability and OSA severity. The data also provide support for reinforcing the importance of ventilatory control in OSA pathogenesis.
觉醒后呼吸暂停/低通气后的过度通气幅度可能会使阻塞性睡眠呼吸暂停(OSA)患者的后续呼吸事件持续存在,从而导致疾病的严重程度增加。由于乙酰唑胺可以降低一些患者的呼吸暂停严重程度,我们研究了乙酰唑胺对 CPAP 治疗的 OSA 患者自发觉醒时通气反应的影响。
我们在 CPAP 治疗的 OSA 患者接受乙酰唑胺治疗 7 天后,评估了觉醒时的通气反应。
睡眠研究实验室。
12 名(7 名男性/5 名女性)接受 CPAP 治疗的 OSA 患者。
口服持续释放乙酰唑胺 500mg,每日两次,持续一周。
一位经过盲法训练的研究人员在非快速眼动睡眠期间识别出自发性觉醒(3-15 秒)。在每个觉醒前 32 秒和后 60 秒,通过呼吸测量分钟通气量、呼气末二氧化碳、潮气量、呼气/吸气时间和总呼吸时间(4 秒间隔)。乙酰唑胺显著增加了静息通气量(7.3 ± 0.2L/min 对 8.2 ± 0.4L/min;P < 0.05),并使觉醒后通气量的增加幅度减少了约 2.5 倍(觉醒前水平 122.0% ± 4.4%对 108.7% ± 3.5%;P < 0.05)。觉醒时通气反应的平均增加与平均 AHI 呈正相关(r²=0.44,P=0.01)。然而,觉醒后通气的绝对峰值水平在两种情况下均保持不变(8.8 ± 0.4L/min 对 8.9 ± 0.1L/min)。
乙酰唑胺显著减弱了 OSA 患者从睡眠中自发觉醒后的通气增加。本研究提示了乙酰唑胺改善通气不稳定和 OSA 严重程度的另一种机制。该数据还为强化通气控制在 OSA 发病机制中的重要性提供了支持。